EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 41 / No 11 (Novembre 2025) Med Sci (Paris), 41 11 (2025) 888-899 References
Issue
Med Sci (Paris)
Volume 41, Number 11, Novembre 2025
L’antibiorésistance au prisme des trois santés
Page(s) 888 - 899
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2025193
Published online 12 December 2025
  1. Waksman SA. What is an antibiotic or an antibiotic substance? Mycologia 1947 ; 39 : 565–9. [Google Scholar]
  2. Gaynes R. The discovery of penicillin—new insights after more than 75 years of clinical use. Emerg Infect Dis 2017 ; 23 : 849–53. [Google Scholar]
  3. Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol 2019 ; 51 : 72–80. [Google Scholar]
  4. Browne AJ, Chipeta MG, Haines-Woodhouse G, et al. Global antibiotic consumption and usage in humans, 2000-18: a spatial modelling study. Lancet Planet Health 2021 ; 5 : e893–e904. [Google Scholar]
  5. Gilmore MC, Cava F. Bacterial peptidoglycan recycling. Trends Microbiol 2025 ; 33 : 340–53. [Google Scholar]
  6. El-Araby AM, Fisher JF, Mobashery S. Bacterial peptidoglycan as a living polymer. Curr Opin Chem Biol 2025 ; 84 : 102562. [Google Scholar]
  7. Massova I, Mobashery S. Kinship and diversification of bacterial penicillin-binding proteins and β-lactamases. Antimicrob Agents Chemother 1998 ; 42 : 1–17. [Google Scholar]
  8. Williams JD. Classification of cephalosporins. Drugs 1987 ; 34 Suppl 2 : 15–22. [Google Scholar]
  9. Bush K, Bradford PA. β-lactams and β-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med 2016 ; 6 : a025247. [Google Scholar]
  10. McCreary EK, Heil EL, Tamma PD. New perspectives on antimicrobial agents: cefiderocol. Antimicrob Agents Chemother 2021 ; 65 : e0217120. [Google Scholar]
  11. Yahav D, Giske CG, Grāmatniece A, et al. New β-lactam–β-lactamase inhibitor combinations. Clin Microbiol Rev 2020 ; 34 : e00115–20. [Google Scholar]
  12. Georgopapadakou N, Hammarström S, Strominger JL. Isolation of the penicillin-binding peptide from D-alanine carboxypeptidase of Bacillus subtilis. Proc Natl Acad Sci USA 1977 ; 74 : 1009–12. [Google Scholar]
  13. Curtis NA, Orr D, Ross GW, et al. Affinities of penicillins and cephalosporins for the penicillin-binding proteins of Escherichia coli K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979 ; 16 : 533–9. [Google Scholar]
  14. Fernandes R, Amador P, Prudêncio C. β-Lactams: chemical structure, mode of action and mechanisms of resistance. Reviews and Research in Medical Microbiology 2013 ; 24 : 7. [Google Scholar]
  15. Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989 ; 8 : 943–50. [Google Scholar]
  16. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 2005 ; 55 Suppl 2 : ii15–20. [Google Scholar]
  17. Kang H-K, Park Y. Glycopeptide antibiotics: structure and mechanisms of action. J Bacteriol Virol 2015 ; 45 : 67. [Google Scholar]
  18. Boulekbache A, Maldonado F, Kavafian R, et al. Comparison of daptomycin and glycopeptide efficacy and safety for the treatment of Gram-positive infections: a systematic review and meta-analysis. J Antimicrob Chemother 2024 ; 79 : 712–21. [Google Scholar]
  19. Hendlin D, Stapley EO, Jackson M, et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 1969 ; 166 : 122–3. [CrossRef] [PubMed] [Google Scholar]
  20. Kahan FM, Kahan JS, Cassidy PJ, et al. The mechanism of action of fosfomycin (phosphonomycin). Ann NY Acad Sci 1974 ; 235 : 364–86. [Google Scholar]
  21. Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev 2016 ; 29 : 321–47. [Google Scholar]
  22. Stansly PG, Schlosser ME. Studies on polymyxin: isolation and identification of bacillus polymyxa and differentiation of polymyxin from certain known antibiotics. J Bacteriol 1947 ; 54 : 549–56. [Google Scholar]
  23. Landman D, Georgescu C, Martin DA, et al. Polymyxins revisited. Clin Microbiol Rev 2008 ; 21 : 449–465. [Google Scholar]
  24. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005 ; 40 : 1333–41. [Google Scholar]
  25. Barbier F, Wolff M. Pseudomonas aeruginosa multirésistant : vers une impasse thérapeutique ?. Med Sci (Paris) 2010 ; 26 : 960–8. [Google Scholar]
  26. Eisenstein BI, Oleson FB Jr, Baltz RH. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis 2010 ; 50 : S10–5. [Google Scholar]
  27. Miller WR, Bayer AS, Arias CA. Mechanism of Action and Resistance to Daptomycin in Staphylococcus aureus and Enterococci. Cold Spring Harb Perspect Med 2016 ; 6 : a026997. [Google Scholar]
  28. Boulekbache A, Maldonado F, Kavafian R, et al. Comparison of daptomycin and glycopeptide efficacy and safety for the treatment of Gram-positive infections: a systematic review and meta-analysis. J Antimicrob Chemother 2024 ; 79 : 712–21. [Google Scholar]
  29. Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother 2003 ; 51 Suppl 1 : 13–20. [Google Scholar]
  30. Van Bambeke F. Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol 2015 ; 10 : 1111–23. [Google Scholar]
  31. Hooper DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb Perspect Med 2016 ; 6 : a025320. [Google Scholar]
  32. Hardie KR, Fenn SJ. JMM profile: rifampicin: a broad-spectrum antibiotic. J Med Microbiol 2022 ; 71. [Google Scholar]
  33. Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 2001 ; 104 : 901–12. [Google Scholar]
  34. Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure–cytotoxicity and resistance mechanisms. Journal of Antimicrobial Chemotherapy 2018 ; 73 : 265–79. [Google Scholar]
  35. Hernández Ceruelos A, Romero-Quezada LC, Ruvalcaba Ledezma JC, et al. Therapeutic uses of metronidazole and its side effects: an update. Eur Rev Med Pharmacol Sci 2019 ; 23 : 397–401. [Google Scholar]
  36. Krause KM, Serio AW, Kane TR, et al. Aminoglycosides: an overview. Cold Spring Harbor Perspectives in Medicine 2016 ; 6 : a027029. [Google Scholar]
  37. Kotra LP, Haddad J, Mobashery S. Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 2000 ; 44 : 3249–56. [CrossRef] [PubMed] [Google Scholar]
  38. Grossman TH. Tetracycline antibiotics and resistance. Cold Spring Harb Perspect Med 2016 ; 6 : a025387. [Google Scholar]
  39. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001 ; 65 : 232–60. [CrossRef] [PubMed] [Google Scholar]
  40. Kunz Coyne AJ, Alosaimy S, Lucas K, et al. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr 2024 ; 12 : e0235123. [Google Scholar]
  41. Schwarz S, Shen J, Kadlec K, et al. Lincosamides, streptogramins, phenicols, and pleuromutilins: mode of action and mechanisms of resistance. Cold Spring Harb Perspect Med 2016 ; 6 : a027037. [Google Scholar]
  42. Vázquez-Laslop N, Mankin AS. How macrolide antibiotics work. Trends Biochem Sci 2018 ; 43 : 668–84. [Google Scholar]
  43. Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol 2003 ; 330 : 1005–14. [Google Scholar]
  44. Burdette SD, Trotman R. Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin Infect Dis 2015 ; 61 : 1315–21. [Google Scholar]
  45. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann NY Acad Sci 2011 ; 1241 : 48–70. [Google Scholar]
  46. Wilson DN, Schluenzen F, Harms JM, et al. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci USA 2008 ; 105 : 13339–44. [Google Scholar]
  47. Balbi HJ. Chloramphenicol: a review. Pediatr Rev 2004 ; 25 : 284–8. [Google Scholar]
  48. Fernandes P. Fusidic Acid: A bacterial elongation factor inhibitor for the oral treatment of acute and chronic staphylococcal infections. Cold Spring Harb Perspect Med 2016 ; 6 : a025437. [Google Scholar]
  49. Capasso C, Supuran CT. Sulfa and trimethoprim-like drugs - antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors. J Enzyme Inhib Med Chem 2014 ; 29 : 379–87. [Google Scholar]
  50. Masters PA, O’Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003 ; 163 : 402–10. [Google Scholar]
  51. Sanders P. Résistance antimicrobienne des bactéries zoonotiques : stratégies actuelles en médecine vétérinaire. Med Sci (Paris) 2010 ; 26 : 930–5. [Google Scholar]
  52. Butler MS, Henderson IR, Capon RJ, et al. Antibiotics in the clinical pipeline as of December 2022. J Antibiot (Tokyo) 2023 ; 76 : 431–73. [CrossRef] [PubMed] [Google Scholar]
  53. Lacotte Y, Jouvin-Marche E, Ploy M-C. EU-JAMRAI - L’Europe s’engage à apporter une réponse coordonnée et à adopter une approche « une seule santé » pour lutter contre la résistance aux antibiotiques. Med Sci (Paris) 2025 ; 41 : 211–2. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.